Core Viewpoint - Nordicus Partners Corporation has applied to uplist its common stock to the Nasdaq Capital Market, aiming to enhance visibility, liquidity, and attract institutional investors following recent acquisitions and advancements in its drug development pipeline [1][2]. Company Overview - Nordicus Partners Corporation is a U.S. publicly traded business accelerator and holding company focused on Nordic life sciences companies, specializing in corporate finance activities such as business development, growth strategies, and capital raising [3]. - In 2024, the company completed two significant acquisitions: 100% of Orocidin A/S, a biotech company developing therapies for periodontitis, and 100% of Bio-Convert A/S, which focuses on treatments for oral leukoplakia [3]. Uplisting Details - The uplisting application to Nasdaq is subject to approval and meeting all listing criteria, with the common stock continuing to trade on the OTCQB Market until the uplisting is finalized [1][2]. - The CEO of Nordicus expressed confidence in meeting the listing requirements, emphasizing the potential benefits of a Nasdaq listing for shareholder value and capital access [2].